Mergers & Acquisitions ·
NextCure, Inc. entered into a merger agreement with Avere Therapeutics, Inc. to undergo a reorganization where Avere…
NXTCNextCure, Inc.
NextCure, Inc. entered into a merger agreement with Avere Therapeutics, Inc. to undergo a reorganization where Avere will become a wholly owned subsidiary of NextCure. Under the terms, Avere stockholders will own approximately 98.11% of the combined company, while NextCure stockholders will own approximately 1.89%. The transaction includes a $320 million private placement of PIPE securities. NextCure also announced a restructuring plan expected to result in a reduction in force and approximately $1.9 million in one-time charges during the third quarter of 2026. Additionally, NextCure decided to stop expanding the clinical site footprint for its SIM0505 program into Europe and Canada and opted out of continued cost-sharing for the LNCB74 program with LigaChem Biosciences. NextCure is a biotechnology company developing antibody-drug conjugates.